ATE353017T1 - Herstellung von impstoffen zür vorbeugung von pathogenen zuständen einer hiv retroviraler infektion - Google Patents

Herstellung von impstoffen zür vorbeugung von pathogenen zuständen einer hiv retroviraler infektion

Info

Publication number
ATE353017T1
ATE353017T1 AT98955673T AT98955673T ATE353017T1 AT E353017 T1 ATE353017 T1 AT E353017T1 AT 98955673 T AT98955673 T AT 98955673T AT 98955673 T AT98955673 T AT 98955673T AT E353017 T1 ATE353017 T1 AT E353017T1
Authority
AT
Austria
Prior art keywords
vaccines
production
retroviral infection
pathogenic conditions
prevent pathogenic
Prior art date
Application number
AT98955673T
Other languages
English (en)
Inventor
Pierre-Francois Serres
Christophe Geourjon
Gilbert Deleage
Christophe Combet
Original Assignee
Mymetics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mymetics Sa filed Critical Mymetics Sa
Application granted granted Critical
Publication of ATE353017T1 publication Critical patent/ATE353017T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT98955673T 1997-11-17 1998-11-17 Herstellung von impstoffen zür vorbeugung von pathogenen zuständen einer hiv retroviraler infektion ATE353017T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9714387A FR2771011B1 (fr) 1997-11-17 1997-11-17 Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale

Publications (1)

Publication Number Publication Date
ATE353017T1 true ATE353017T1 (de) 2007-02-15

Family

ID=9513450

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98955673T ATE353017T1 (de) 1997-11-17 1998-11-17 Herstellung von impstoffen zür vorbeugung von pathogenen zuständen einer hiv retroviraler infektion

Country Status (19)

Country Link
US (3) US6455265B1 (de)
EP (1) EP1034000B1 (de)
JP (1) JP4837823B2 (de)
KR (1) KR20010032210A (de)
CN (1) CN1281371A (de)
AP (1) AP2000001841A0 (de)
AT (1) ATE353017T1 (de)
AU (1) AU1243499A (de)
BR (1) BR9814204A (de)
CA (1) CA2309676C (de)
DE (1) DE69837012T2 (de)
DK (1) DK1034000T3 (de)
EA (1) EA200000528A1 (de)
ES (1) ES2281938T3 (de)
FR (1) FR2771011B1 (de)
IL (2) IL136163A0 (de)
OA (1) OA11522A (de)
PT (1) PT1034000E (de)
WO (1) WO1999025377A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
CN1396178A (zh) * 2002-06-17 2003-02-12 成都阳辉生物科技有限责任公司 抗乙肝病毒等包膜病毒感染的工程多肽及其制备方法
ATE508139T1 (de) 2003-04-11 2011-05-15 Pasteur Institut Synthetische peptid-hiv-vakzine: das cbd-epitop als effizientes immunogen zur induktion hiv- neutralisierender antikörper
CN1860130B (zh) 2003-07-30 2012-05-30 迈梅蒂克斯公司 新的可溶且稳定的三聚体形式的gp41多肽
WO2006011919A1 (en) * 2004-06-30 2006-02-02 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7201903B2 (en) * 2003-09-11 2007-04-10 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7285272B2 (en) * 2003-12-18 2007-10-23 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
DE602005027326D1 (de) * 2004-02-19 2011-05-19 Idexx Lab Inc Verfahren und vorrichtung zum nachweis von katzen-immunschwächevirus
US8178657B2 (en) * 2004-03-30 2012-05-15 Institut Gustave Roussy Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins
US7335360B2 (en) * 2004-06-30 2008-02-26 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
WO2006011917A1 (en) * 2004-06-30 2006-02-02 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US20090232826A1 (en) * 2005-05-02 2009-09-17 Mymetics Corporation Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2
TWI343180B (en) * 2005-07-01 2011-06-01 Ind Tech Res Inst The acoustic wave sensing-device integrated with micro channels
WO2007099387A1 (en) * 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
CN1869704B (zh) * 2006-06-14 2010-06-30 厦门大学 快速鉴定与病原菌互作的宿主蛋白的方法
US20110195089A1 (en) * 2008-10-08 2011-08-11 The Adminstrators Of The Tulane Educational Fund Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
EP2393510A1 (de) 2009-02-06 2011-12-14 Mymetics Corporation Neue gp41-antigene
MX2011007745A (es) 2009-02-06 2011-12-08 Mymetics Corp Division de gp41.
US20120148594A1 (en) * 2009-08-21 2012-06-14 Dana-Farber Cancer Institute, Inc. Mimotopes of hiv and uses thereof
WO2011123781A1 (en) 2010-04-02 2011-10-06 Idexx Laboratories, Inc. Detection of feline immunodeficiency virus
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CN104717976A (zh) 2012-08-30 2015-06-17 梅里亚有限公司 嵌合ksac蛋白的表达和由高压产生可溶性蛋白的方法
WO2021185851A1 (en) 2020-03-17 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine compositions for hiv prevention and treatment
CN111701016A (zh) * 2020-06-28 2020-09-25 张全志 逆转录病毒原病毒序列在逆转录病毒疫苗设计中的应用
CN118515733A (zh) * 2023-02-20 2024-08-20 菲鹏生物股份有限公司 Hiv蛋白及其在检测hiv抗体中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001304A1 (en) * 1991-07-10 1993-01-21 Synbiotics Corporation Synthetic peptides related to fiv-env proteins
WO1994002505A1 (en) * 1992-07-20 1994-02-03 Duke University Compounds which inhibit hiv replication
GB9219936D0 (en) * 1992-09-21 1992-11-04 Pitman Moore Inc Vaccines
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale

Also Published As

Publication number Publication date
IL136163A (en) 2007-07-04
EP1034000A1 (de) 2000-09-13
IL136163A0 (en) 2001-05-20
US7829683B2 (en) 2010-11-09
DE69837012T2 (de) 2007-11-29
US20040014046A1 (en) 2004-01-22
AU1243499A (en) 1999-06-07
KR20010032210A (ko) 2001-04-16
WO1999025377A1 (fr) 1999-05-27
EP1034000B1 (de) 2007-01-31
FR2771011A1 (fr) 1999-05-21
AP2000001841A0 (en) 2000-06-30
CA2309676A1 (fr) 1999-05-27
CA2309676C (fr) 2012-08-07
FR2771011B1 (fr) 2000-01-28
ES2281938T3 (es) 2007-10-01
US7253270B2 (en) 2007-08-07
EA200000528A1 (ru) 2001-02-26
JP2001524456A (ja) 2001-12-04
DK1034000T3 (da) 2007-06-04
US20050048478A9 (en) 2005-03-03
JP4837823B2 (ja) 2011-12-14
US20080003229A1 (en) 2008-01-03
CN1281371A (zh) 2001-01-24
OA11522A (fr) 2004-02-09
DE69837012D1 (de) 2007-03-22
BR9814204A (pt) 2000-10-03
PT1034000E (pt) 2007-05-31
US6455265B1 (en) 2002-09-24

Similar Documents

Publication Publication Date Title
ATE353017T1 (de) Herstellung von impstoffen zür vorbeugung von pathogenen zuständen einer hiv retroviraler infektion
DE3780933D1 (de) Herstellung von aminoalanen.
DE69408679D1 (de) Herstellung von geformten faserstrukturen
DE69117356D1 (de) Herstellung von Aluminoxanen
DE69531834D1 (de) Herstellung einer aerosolformulierung von insulin
DE69008155D1 (de) Herstellung von Stoffliesen.
ATE131185T1 (de) Herstellung von peroxidhaltigen perfluorpolyethern.
DE69812901D1 (de) Katalytische herstellung von pentafluorpropenen
DE3751124D1 (de) Faseroptischer Modekonverter.
DE3686547D1 (de) Herstellung von harnstoff-polyaminharzen fuer papierbekleidungszusammensetzungen.
DE3786282D1 (de) Herstellung von nahtlosen traegern.
FI872295A0 (fi) Pendimetaliinin väkevöityjä vesisuspensiokoostumuksia
DE69116826D1 (de) Herstellung von Alkoxyalkansäuren
DE60019960D1 (de) Herstellung von isobutencopolymere
DE69503632D1 (de) Herstellung von enthydroxylierten träger
DE69410266D1 (de) Herstellung von dimethyl cyclohexandicarboxylaten
DE3688937D1 (de) Herstellung optisch aktiver aryloxypropanolamine und arylaethanolamine.
DE3766559D1 (de) Herstellung von kristallinem tribromstyrol.
DE3789316D1 (de) Herstellung von human-parathyroidhormon.
DE3778134D1 (de) Kontinuierliche herstellung von dialkansulfonylperoxiden.
DE3689971D1 (de) Herstellung einer halbleiteranordnung.
DE69213862D1 (de) Herstellung von Aluminoxanen
DE3584300D1 (de) Herstellung von malaria-impfstoffen.
DE3752115D1 (de) Herstellung einer Dioxazinverbindung
DE69502001D1 (de) Herstellung von uranoxid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1034000

Country of ref document: EP